国泰海通证券股份有限公司 关于重庆智翔金泰生物制药股份有限公司 2024 年度募集资金存放与使用情况的专项核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐机构"）作为 重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"或"公司"）的持 续督导机构，根据《证券发行上市保荐业务管理办法》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求》《上海证券交易所科创板股票 上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》 等相关规定，对智翔金泰 2024 年度募集资金存放与使用情况进行了审慎核查， 具体情况如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 根据中国证券监督管理委员会《关于同意重庆智翔金泰生物制药股份有限公 司首次公开发行股票注册的批复》（证监许可〔2023〕725 号），公司首次公开 发行人民币普通股 9,168.00 万股，发行价格为每股 37.88 元，募集资金总额为 347,283.84 万元，扣除发行费用后募集资金净额为 329,140.14 万元。信永中和会 计师事务所（特殊普通合伙）对公司本次公开发行新股的资金 ...

重庆智翔金泰生物制药股份有限公司 2024 年度 审计报告 | 索引 | 页码 | | --- | --- | | 审计报告 | 1-5 | | 公司财务报表 | | | 合并资产负债表 | 1-2 | | 母公司资产负债表 | 3-4 | | 合并利润表 | 5 | | 母公司利润表 | 6 | | 合并现金流量表 | 7 | | 母公司现金流量表 | 8 | | 合并股东权益变动表 | 9-10 | | 母公司股东权益变动表 | 11-12 | | 财务报表附注 | 13-71 | 信永中和会计师事务所 | 北京市东城区朝阳门北大街 8 号富华大厦 A 座 9 层 +86 (010) 6554 2288 telephone: +86 (010) 6554 2288 9/F. Block A. Fu Hua Mansion No.8. Chaovangmen Beidajie Donachena District, Beijing certified public accountants 100027. P.R.China 86 (010) 6554 7190 +86 (010) 6554 7190 审计报 ...

国泰海通证券股份有限公司 关于重庆智翔金泰生物制药股份有限公司 2024 年度持续督导年度跟踪报告 | 保荐机构名称：国泰海通证券股份有限公司 | 被保荐公司简称：智翔金泰 | | --- | --- | | 保荐代表人姓名：王永杰、刘丹 | 被保荐公司代码：688443 | 重大事项提示 公司是一家创新驱动型生物制药企业，产品为自身免疫性疾病、感染性疾 病和肿瘤等治疗领域的单克隆抗体药物和双特异性抗体药物。 截至 2024 年 12 月 31 日，公司尚未盈利且存在累计未弥补亏损，主要由于 新药研发、生产、商业化是一个长周期、高投入、高风险的过程，公司在药物 早期发现、临床前研究、临床研究、工艺开发、生产、商业化推广等多个环节 持续投入，营业收入尚不能覆盖研发费用及其他开支。 报告期内，公司各项目研发快速推进，人才梯队建设不断完善，商业化能 力逐步兑现，现金储备情况良好，核心管理及研发团队稳定。随着更多在研产 品逐步实现商业化以及已上市产品更多适应症的拓展，公司的财务状况与持续 经营能力将进一步改善。 经中国证券监督管理委员会《关于同意重庆智翔金泰生物制药股份有限公司 首次公开发行股票注册的批复》（证监许可 ...

重庆智翔金泰生物制药股份有限公司 独立董事 2024 年度述职报告 作为重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"或"公司"） 首届董事会的独立董事，我始终严格遵循《中华人民共和国公司法》《中华人民 共和国证券法》《上市公司独立董事管理办法》等法律法规以及《重庆智翔金泰 生物制药股份有限公司章程》（以下简称《公司章程》）《独立董事工作制度》的 规范要求，秉持客观、公正、独立的立场，充分发挥自身专业优势，审慎行使独 立董事职权。任职期间，我积极出席公司董事会及股东大会，深度参与公司重大 决策，针对关键事项发表独立、客观的意见，切实维护公司整体利益及广大股东 尤其是中小股东的合法权益。通过严谨履职、勤勉尽责，我忠实履行了独立董事 的诚信义务，为公司稳健发展贡献了专业力量，彰显了独立董事在公司治理中的 重要作用。 本人因任期届满于 2024 年 12 月 24 日，公司召开 2024 年第一次临时股东大 会选举产生新任独立董事后正式离任，不再担任公司董事会独立董事及各专门委 员会中相关职务。 现将本人 2024 年度的履职情况报告如下： 一、独立董事基本情况 （一）个人工作履历、专业背景及兼职情况 本人 ...

重庆智翔金泰生物制药股份有限公司 独立董事 2024 年度述职报告 作为重庆智翔金泰生物制药股份有限公司（以下简称"智翔金泰"或"公司"） 董事会的独立董事，本人严格按照《中华人民共和国公司法》《中华人民共和国 证券法》《上市公司独立董事管理办法》等相关法律法规和规章制度的规定及《重 庆智翔金泰生物制药股份有限公司章程》（以下简称《公司章程》）《独立董事工 作制度》的要求，严格遵循客观、公正、独立的履职原则，依托专业能力审慎行 使独董职权，通过全程参与董事会及股东大会，在重大决策中发表意见，切实维 护公司整体利益与中小投资者权益，忠实履行勤勉义务，为完善公司治理作出专 业贡献。 报告期内，公司第一届董事会于 2024 年 12 月 24 日完成换届选举，本人继 续担任公司第二届董事会独立董事，并履行董事会专门委员会相关职务。 现将本人 2024 年度的履职情况报告如下： 一、独立董事基本情况 （一）个人工作履历、专业背景及兼职情况 胡耘通先生，1982 年 11 月出生，中国国籍，无境外居留权，中国注册会计 师、法学博士、教授。2011 年 6 月至今，任西南政法大学教授；2011 年 11 月至 今，任重庆 ...

Financial Performance - The company's operating revenue for Q1 2025 was ¥20,155,818.67, a significant increase compared to the previous year's revenue of ¥6,330.27[4] - The net profit attributable to shareholders was -¥120,722,370.11, an improvement from -¥163,770,017.01 in the same period last year[4] - The net cash flow from operating activities was -¥110,686,349.98, compared to -¥144,561,278.97 in the previous year, indicating a reduction in cash outflow[4] - The weighted average return on net assets was -5.85%, showing a slight improvement from -6.04% in the previous year[4] - The net loss for Q1 2025 was ¥120,722,370.11, an improvement compared to a net loss of ¥163,770,017.01 in Q1 2024[20] - Basic and diluted earnings per share for Q1 2025 were both -¥0.33, compared to -¥0.45 in Q1 2024[20] Research and Development - Research and development expenses totaled ¥102,720,212.86, representing 509.63% of the operating revenue, reflecting a strong commitment to innovation[5] - The company continues to focus on expanding its product offerings and enhancing its market presence through ongoing research and development efforts[5] - The company has made progress in multiple research projects, with the approval of GR1501 for ankylosing spondylitis expected in January 2025[12] - The new drug application for GR1801 was accepted by the National Medical Products Administration (NMPA) in January 2025, indicating ongoing product development[12] - The company initiated Phase III clinical trials for GR1802 for chronic spontaneous urticaria in February 2025, showcasing its commitment to advancing its product pipeline[13] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,090,298,999.64, a decrease of 1.76% from the previous year's total assets of ¥3,145,716,912.53[5] - The total assets decreased from ¥3,145,716,912.53 to ¥3,090,298,999.64[17] - Total liabilities increased from ¥1,019,674,124.99 to ¥1,089,672,459.36[17] - The owner's equity attributable to the parent company decreased from ¥2,126,042,787.54 to ¥2,000,626,540.28[17] Cash Flow - As of March 31, 2025, the company's cash and cash equivalents amounted to ¥1,691,163,876.90, a decrease from ¥2,035,452,759.61 on December 31, 2024, representing a decline of approximately 17%[15] - The company's total current assets as of March 31, 2025, were ¥2,577,321,842.11, slightly down from ¥2,622,157,525.64 at the end of 2024, indicating a decrease of about 1.7%[15] - The company reported an increase in trading financial assets to ¥711,494,583.33 as of March 31, 2025, compared to ¥412,583,750.00 at the end of 2024, reflecting a growth of approximately 72%[15] - The accounts receivable rose to ¥15,004,941.09 from ¥12,007,485.25, marking an increase of about 25%[15] - The total cash outflow from operating activities was 160,623,910.13 RMB in Q1 2025, slightly higher than 158,287,926.91 RMB in Q1 2024[22] - The company received 30,314,468.83 RMB in other cash related to operating activities in Q1 2025, compared to 13,726,647.94 RMB in Q1 2024[22] - The company paid 79,098,052.94 RMB to employees in Q1 2025, an increase from 57,285,349.85 RMB in Q1 2024[22] - The cash outflow for taxes in Q1 2025 was 3,318,639.41 RMB, compared to 1,289,303.93 RMB in Q1 2024[22] - The company’s total cash inflow from operating activities was 49,937,560.15 RMB in Q1 2025, compared to 13,726,647.94 RMB in Q1 2024[22] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 9,205, indicating a stable shareholder base[8] - The top ten shareholders include significant institutional investors, with China Construction Bank holding 5,000,000 shares, representing 1.36% of total shares[11] - The company has not reported any changes in the participation of major shareholders in margin trading or securities lending activities[11]

Financial Performance - The company reported product sales revenue of CNY 30.07 million as of December 31, 2024, marking its entry into the commercialization phase of innovative drugs [3]. - The company's revenue for 2024 reached ¥30,094,960.64, a significant increase of 2,384.10% compared to ¥1,211,502.42 in 2023, primarily due to the commercialization of the monoclonal antibody injection (金立希®) [24]. - The net loss attributable to shareholders for 2024 was ¥797,273,629.92, a slight improvement from a loss of ¥801,319,298.24 in 2023 [24]. - The net cash flow from operating activities for 2024 was -¥575,436,992.24, which increased from -¥377,580,702.25 in 2023, reflecting expanded operations and increased personnel costs [24]. - The basic earnings per share for 2024 was -¥2.17, compared to -¥2.50 in 2023, indicating a narrowing of losses [25]. - The company's total assets decreased by 12.49% to ¥3,145,716,912.53 at the end of 2024, down from ¥3,594,596,738.24 in 2023 [24]. - Financial expenses decreased compared to the previous year, contributing to the narrowing of net losses [24]. - The company reported a cash flow from operating activities of -152,925,921.04 RMB in Q4, indicating ongoing financial challenges [28]. - The company achieved sales revenue of 30,069,600 RMB from the newly launched drug, Saliqi monoclonal antibody injection, benefiting nearly 10,000 psoriasis patients [36]. Research and Development - Research and development expenses for the reporting period amounted to CNY 609.79 million, with a cumulative investment of CNY 1.68 billion over the past three years [4]. - The company plans to maintain high levels of R&D investment as several products enter critical registration clinical stages [4]. - The research and development expenditure as a percentage of revenue was exceptionally high at 2,026.23% for 2024, reflecting significant investment in new product development [26]. - The company is focused on accelerating product research and development to meet unmet clinical needs in the pharmaceutical sector [34]. - The company has established a dual-specific antibody discovery technology platform, enhancing its competitive edge in drug development [43]. - The company has 14 products in the pipeline, with 2 indications of the monoclonal antibody GR1501 approved for market, and GR1802's NDA accepted [47]. - The company has made significant progress in product development and commercialization in response to ongoing reforms in the pharmaceutical industry [34]. - The company has established a comprehensive system for R&D, procurement, production, and quality control [62]. - The company has established multiple quality research and analysis platforms to meet the quality control requirements of innovative biopharmaceuticals [69]. Commercialization Efforts - The company is focusing on advancing multiple projects in clinical research and has established a commercial sales team [4]. - The company plans to continue expanding its commercialization efforts following the approval of its new product, which has already started generating sales revenue [24]. - The company has established a commercialization team of nearly 200 people to enhance the marketing system for autoimmune disease products [36]. - The company signed strategic cooperation agreements with several well-known domestic distributors to enhance drug accessibility and overall sales effectiveness [36]. - The company is actively expanding its commercialization process and accelerating the construction of industrialization bases [47]. - The company is focused on increasing its operational scale and enhancing its workforce to support ongoing research and development initiatives [24]. Market and Industry Outlook - The biopharmaceutical market in China is expected to reach CNY 131.98 billion by 2030, with a compound annual growth rate (CAGR) of 14.4% from 2018 to 2030 [73]. - The global biopharmaceutical market is projected to reach USD 665.1 billion by 2030, with a CAGR of 8.1% from 2018 to 2030 [73]. - The increasing prevalence of cancer and autoimmune diseases is driving the demand for biopharmaceuticals in China, supported by improved healthcare awareness and diagnostic technologies [73]. - The penetration rate of innovative targeted biopharmaceuticals in clinical treatments is expected to continue rising, offering significant market potential [73]. - The biopharmaceutical industry is characterized by long R&D cycles and high risks, which may lead to further short-term losses for the company [5]. Governance and Management - The company has a stable core management and R&D team, with good cash reserves [4]. - The company emphasizes talent development and strategic reserve, enhancing its innovation capabilities through a comprehensive talent ecosystem [39]. - The company is committed to improving its governance structure and internal management efficiency to comply with relevant laws and regulations [164]. - The company has established a comprehensive compensation policy that includes basic salary, performance bonuses, and various benefits [190]. - The company has a performance-based salary adjustment mechanism to align individual performance with company results [190]. Risks and Challenges - The company has not yet achieved profitability and has accumulated losses due to high investment in drug development and commercialization processes [3]. - The company emphasizes the importance of monitoring investment risks due to potential adverse impacts on financial conditions from ongoing R&D expenditures [5]. - The company is facing risks related to market competition, drug pricing policies, and potential loss of core technical personnel, which could adversely affect its business operations [105][106][111]. - The company's commercialization efforts are still in the early stages, which may lead to uncertainties in profitability if results do not meet expectations [102].

重庆智翔金泰生物制药股份有限公司 2024 年度"提质增效重回报"行动方案评估报告 及 2025 年度行动方案 为积极响应上海证券交易所关于开展科创板上市公司"提质增效重回报"专项 行动的倡议，践行"以投资者为本"的发展理念，持续推动企业高质量发展，积极 承担上市公司责任，提升投资价值，重庆智翔金泰生物制药股份有限公司（以下简 称"公司"）于 2024 年 7 月 16 日发布了《重庆智翔金泰生物制药股份有限公司 2024 年度"提质增效重回报"行动方案》。为进一步提高公司质量、提升公司投资价值， 结合公司 2024 年度行动方案执行情况，公司制定了《重庆智翔金泰生物制药股份 有限公司 2024 年度"提质增效重回报"行动方案评估报告及 2025 年度行动方案》。 该方案于 2025 年 4 月 25 日经公司第二届董事会第二次会议审议通过，现将相关方 案报告如下： 一、聚焦主营业务，创新驱动，持续加大研发投入 公司是一家创新驱动型生物制药企业，主营业务为抗体药物的研发、生产与销 售，公司在研产品为单克隆抗体药物和双特异性抗体药物。 公司在源头创新方面建立了基于新型噬菌体呈现系统的单抗药物发现技术平 台和双特 ...

●重庆智翔金泰生物制药股份有限公司（以下简称"公司"）拟使用额度不 超过人民币 50,000 万元（含本数）的闲置募集资金临时补充流动资金，用于与 公司主营业务相关的生产经营。 ●使用期限自公司董事会审议通过之日起不超过 12 个月 证券代码：688443 证券简称：智翔金泰 公告编号：2025-016 重庆智翔金泰生物制药股份有限公司 关于使用部分闲置募集资金临时补充流动资金公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司于 2025 年 4 月 25 日召开第二届董事会第二次会议、第二届监事会第二 次会议，审议通过了《关于使用部分闲置募集资金临时补充流动资金的议案》， 根据公司募集资金投资项目的资金使用计划及项目的建设进度，公司在确保不影 响募集资金投资项目建设进度，不改变募集资金用途，不影响募集资金投资计划 正常进行的前提下，为了提高募集资金使用效率、降低公司财务成本、解决公司 运营发展的资金需求，董事会同意公司以部分闲置募集资金临时补充流动资金。 现将相关事项公告如下： 一、募集资金基本情况 ...

关于独立董事独立性情况的专项意见 根据《上市公司独立董事管理办法》《上海证券交易所科创板上市公司自律 监管指引第 1 号——规范运作》等法律法规及重庆智翔金泰生物制药股份有限公 司(以下简称"公司")《重庆智翔金泰生物制药股份有限公司章程》《独立董事 工作制度》的规定，公司董事会就公司在任独立董事崔萱林、陈利、胡耘通的独 立性情况进行评估并出具如下专项意见： 经核查独立董事崔萱林、陈利、胡耘通及其直系亲属和主要社会关系人员的 任职经历以及独立董事签署的相关自查文件，独立董事崔萱林、陈利、胡耘通不 存在《上市公司独立董事管理办法》第六条不得担任独立董事的情形，在担任公 司独立董事期间，严格遵守中国证监会和上海证券交易所的相关规定，确保有足 够的时间和精力勤勉尽责地履行职责，作出独立判断，不受公司主要股东、实际 控制人或其他与公司存在利害关系的单位或个人的影响。公司独立董事崔萱林、 陈利、胡耘通符合《上市公司独立董事管理办法》《上海证券交易所科创板上市 公司自律监管指引第 1 号——规范运作》等相关法律法规以及《重庆智翔金泰生 物制药股份有限公司章程》《独立董事工作制度》等内部制度中对独立董事独立 性的相关要求。 ...